Skip to content
drillr.ai
Sign up

JNJ

JOHNSON & JOHNSON

NYSE · Healthcare · Drug Manufacturers - General · US

$272.08
+2.22%
Ask drillr

  • Sep 25, 2026, 11:30 UTC

    Johnson & Johnson announced that TREMFYA met its primary and key secondary endpoints in a study of axial psoriatic arthritis.

    Source:

  • Sep 25, 2026, 11:02 UTC

    Johnson & Johnson announced that CARVYKTI achieved five-year treatment-free remission in 50% of patients with early relapsed or refractory multiple myeloma.

    Source:

  • Sep 23, 2026, 17:45 UTC

    AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.

    Source:

  • Sep 23, 2026, 14:17 UTC

    Johnson & Johnson reported new data from the Phase 3 MAJESTEC-3 study.

    Source:

  • Sep 23, 2026, 13:49 UTC

    Johnson & Johnson announced that its TECVAYLI combined with DARZALEX FASPRO regimen reduces the risk of disease progression in multiple myeloma by 90% versus standard therapy.

    Source:

  • Sep 21, 2026, 12:50 UTC

    Johnson & Johnson announced that its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, advancing the drug toward expanded approval.

    Source:

  • Sep 18, 2026, 01:58 UTC

    Johnson & Johnson's Abiomed unit is removing every Automated Impella Controller worldwide to replace parts linked to failures associated with 37 serious injuries and three deaths, per an FDA early alert.

    Source:

  • Sep 17, 2026, 21:18 UTC

    PepsiCo appointed Joaquin Duato, Johnson & Johnson's Chairman and CEO, as an independent member of its Board effective December 1, 2026.

  • Sep 16, 2026, 11:49 UTC

    Johnson & Johnson announced the launch in China of Rybrevant (amivantamab) subcutaneous injection, in combination with Lazcluze (lazertinib), for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

    Source:

  • Sep 15, 2026, 14:15 UTC

    Nebraska counties and cities received shares of nationwide opioid settlements totaling more than $50 billion, with Nebraska's portion exceeding $150 million over 18 years, and at least nine counties and cities spent at least $88,800 of those funds on law enforcement tools including Flock Safety license plate reader cameras.

    Source:

  • Sep 15, 2026, 04:08 UTC

    Defensive stocks including Johnson & Johnson, Eli Lilly, Kimberly-Clark, Costco, CrowdStrike and Palo Alto Networks rallied on Monday as Wall Street rotated out of AI infrastructure names, while Meta Platforms, Alphabet and Microsoft also advanced.

    Source:

  • Sep 15, 2026, 03:00 UTC

    Johnson & Johnson announced new Phase 2b COPERNICUS study results at WCLC 2026 showing low rates of treatment-related events with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in previously untreated advanced EGFR-mutated non-small cell lung cancer.

    Source:

  • Sep 14, 2026, 20:38 UTC

    Contineum Therapeutics announced that an experimental depression drug developed with Johnson & Johnson failed to meet the main goal of a mid-stage clinical trial.

    Source:

  • Sep 14, 2026, 01:46 UTC

    Johnson & Johnson announced that RYBREVANT combined with chemotherapy achieved the longest reported median overall survival in EGFR exon 20 insertion-mutated non-small cell lung cancer.

    Source:

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 10, 2026, 15:15 UTC

    NICE issued Final Draft Guidance recommending Johnson & Johnson's Imbruvica (ibrutinib) with R-CHOP, alternating with R-DHAP or R-DHAOx followed by ibrutinib monotherapy, for adults with previously untreated mantle cell lymphoma suitable for autologous stem cell transplant in the UK.

    Source:

  • Sep 10, 2026, 11:45 UTC

    Johnson & Johnson received CE Marking for its ACUVUE OASYS MAX 2-Week reusable contact lenses.

    Source:

  • Sep 9, 2026, 03:30 UTC

    The APEC Business Advisory Council upgraded its Supply Chain Resilience Toolkit, adding an AI-enabled tariff tool and expanding it to seven languages, to help small businesses manage supply chain risks and trade compliance.

    Source:

  • Sep 8, 2026, 20:05 UTC

    Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.

    Source:

  • Aug 25, 2026, 00:00 UTC

    Parabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.

  • Aug 24, 2026, 22:33 UTC

    The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's drug to treat a rare blood disorder, announced by the company on Monday.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 3, 2026, 00:00 UTC

    Lipocine Inc. appointed Michael J. Grissinger as a director, effective August 3, 2026, with an initial stock option grant to purchase 2,000 shares of common stock.

    Source:
← PreviousPage 2Next →